EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES

EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES

A prespecified subgroup analysis of an open-label study evaluating an AML/OM-based regimen in Blacks and Non-Blacks with type 2 diabetes and hypertension is reported. Drug-related treatment-emergent adverse events (DR-TEAEs) were experienced by 20.0% and 19.2% of Blacks and Non-Blacks, respectively....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ethnicity & disease 2010-09, Vol.20 (4), p.np-np
Hauptverfasser: Ram, C V S, Neutel, J M, Shojaee, A, Stoakes, K A, Qian, C
Format: Artikel
Sprache:eng
Schlagworte:
African Americans
Comparative studies
Diabetes
Drug therapy
Effectiveness
Health and Medicine
Hypertension
Medical research
Side Effects
Statistical Data
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page np
container_issue 4
container_start_page np
container_title Ethnicity & disease
container_volume 20
creator Ram, C V S
Neutel, J M
Shojaee, A
Stoakes, K A
Qian, C
description A prespecified subgroup analysis of an open-label study evaluating an AML/OM-based regimen in Blacks and Non-Blacks with type 2 diabetes and hypertension is reported. Drug-related treatment-emergent adverse events (DR-TEAEs) were experienced by 20.0% and 19.2% of Blacks and Non-Blacks, respectively. AML/OM plus hydrochlorothiazide enabled significant BP reductions and BP target achievements, and was well-tolerated.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2586833323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586833323</sourcerecordid><originalsourceid>FETCH-proquest_journals_25868333233</originalsourceid><addsrcrecordid>eNqNjc1OwzAQhH0AifLzDitxaQ-W0jhB5ejEm2aF7Y3ilSinikM5VIhCQ9-HR8UCHoDTzHwz0pyp2bKo7nW9LDYX6nKa9kVR1nVVzdQXdh22koA7sBFs8OxooIgwz36hM3TAPmCyo-RBQMcbDuRhzmGhG5vQgZCMVlAL6zVbDyOuKWAEitB42z4AjxA56t8wWCGM-fKRpIf-acBRMCbi-HMmGUAJjmyDgulanb88v067mz-9UrcdStvr9-Ph47SbPrf7w-n4lqttWa_uVsaY0pj_rb4BuitLEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586833323</pqid></control><display><type>article</type><title>EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>JSTOR Archive Collection A-Z Listing</source><creator>Ram, C V S ; Neutel, J M ; Shojaee, A ; Stoakes, K A ; Qian, C</creator><creatorcontrib>Ram, C V S ; Neutel, J M ; Shojaee, A ; Stoakes, K A ; Qian, C</creatorcontrib><description>A prespecified subgroup analysis of an open-label study evaluating an AML/OM-based regimen in Blacks and Non-Blacks with type 2 diabetes and hypertension is reported. Drug-related treatment-emergent adverse events (DR-TEAEs) were experienced by 20.0% and 19.2% of Blacks and Non-Blacks, respectively. AML/OM plus hydrochlorothiazide enabled significant BP reductions and BP target achievements, and was well-tolerated.</description><identifier>ISSN: 1049-510X</identifier><language>eng</language><publisher>Palm Coast: International Society on Hypertension in Blacks</publisher><subject>African Americans ; Comparative studies ; Diabetes ; Drug therapy ; Effectiveness ; Health and Medicine ; Hypertension ; Medical research ; Side Effects ; Statistical Data ; United States</subject><ispartof>Ethnicity &amp; disease, 2010-09, Vol.20 (4), p.np-np</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Ram, C V S</creatorcontrib><creatorcontrib>Neutel, J M</creatorcontrib><creatorcontrib>Shojaee, A</creatorcontrib><creatorcontrib>Stoakes, K A</creatorcontrib><creatorcontrib>Qian, C</creatorcontrib><title>EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES</title><title>Ethnicity &amp; disease</title><description>A prespecified subgroup analysis of an open-label study evaluating an AML/OM-based regimen in Blacks and Non-Blacks with type 2 diabetes and hypertension is reported. Drug-related treatment-emergent adverse events (DR-TEAEs) were experienced by 20.0% and 19.2% of Blacks and Non-Blacks, respectively. AML/OM plus hydrochlorothiazide enabled significant BP reductions and BP target achievements, and was well-tolerated.</description><subject>African Americans</subject><subject>Comparative studies</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Health and Medicine</subject><subject>Hypertension</subject><subject>Medical research</subject><subject>Side Effects</subject><subject>Statistical Data</subject><subject>United States</subject><issn>1049-510X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNjc1OwzAQhH0AifLzDitxaQ-W0jhB5ejEm2aF7Y3ilSinikM5VIhCQ9-HR8UCHoDTzHwz0pyp2bKo7nW9LDYX6nKa9kVR1nVVzdQXdh22koA7sBFs8OxooIgwz36hM3TAPmCyo-RBQMcbDuRhzmGhG5vQgZCMVlAL6zVbDyOuKWAEitB42z4AjxA56t8wWCGM-fKRpIf-acBRMCbi-HMmGUAJjmyDgulanb88v067mz-9UrcdStvr9-Ph47SbPrf7w-n4lqttWa_uVsaY0pj_rb4BuitLEw</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Ram, C V S</creator><creator>Neutel, J M</creator><creator>Shojaee, A</creator><creator>Stoakes, K A</creator><creator>Qian, C</creator><general>International Society on Hypertension in Blacks</general><scope/></search><sort><creationdate>20100901</creationdate><title>EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES</title><author>Ram, C V S ; Neutel, J M ; Shojaee, A ; Stoakes, K A ; Qian, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_25868333233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>African Americans</topic><topic>Comparative studies</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Health and Medicine</topic><topic>Hypertension</topic><topic>Medical research</topic><topic>Side Effects</topic><topic>Statistical Data</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ram, C V S</creatorcontrib><creatorcontrib>Neutel, J M</creatorcontrib><creatorcontrib>Shojaee, A</creatorcontrib><creatorcontrib>Stoakes, K A</creatorcontrib><creatorcontrib>Qian, C</creatorcontrib><jtitle>Ethnicity &amp; disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ram, C V S</au><au>Neutel, J M</au><au>Shojaee, A</au><au>Stoakes, K A</au><au>Qian, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES</atitle><jtitle>Ethnicity &amp; disease</jtitle><date>2010-09-01</date><risdate>2010</risdate><volume>20</volume><issue>4</issue><spage>np</spage><epage>np</epage><pages>np-np</pages><issn>1049-510X</issn><abstract>A prespecified subgroup analysis of an open-label study evaluating an AML/OM-based regimen in Blacks and Non-Blacks with type 2 diabetes and hypertension is reported. Drug-related treatment-emergent adverse events (DR-TEAEs) were experienced by 20.0% and 19.2% of Blacks and Non-Blacks, respectively. AML/OM plus hydrochlorothiazide enabled significant BP reductions and BP target achievements, and was well-tolerated.</abstract><cop>Palm Coast</cop><pub>International Society on Hypertension in Blacks</pub></addata></record>
fulltext fulltext
identifier ISSN: 1049-510X
ispartof Ethnicity & disease, 2010-09, Vol.20 (4), p.np-np
issn 1049-510X
language eng
recordid cdi_proquest_journals_2586833323
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; JSTOR Archive Collection A-Z Listing
subjects African Americans
Comparative studies
Diabetes
Drug therapy
Effectiveness
Health and Medicine
Hypertension
Medical research
Side Effects
Statistical Data
United States
title EFFECTS OF AN AMLODIPINE (AML)- AND OLMESARTAN MEDOXOMIL (OM)-BASED TITRATE-TO-GOAL REGIMEN IN BLACK OR NON-BLACK PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T04%3A20%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EFFECTS%20OF%20AN%20AMLODIPINE%20(AML)-%20AND%20OLMESARTAN%20MEDOXOMIL%20(OM)-BASED%20TITRATE-TO-GOAL%20REGIMEN%20IN%20BLACK%20OR%20NON-BLACK%20PATIENTS%20WITH%20HYPERTENSION%20AND%20TYPE%202%20DIABETES&rft.jtitle=Ethnicity%20&%20disease&rft.au=Ram,%20C%20V%20S&rft.date=2010-09-01&rft.volume=20&rft.issue=4&rft.spage=np&rft.epage=np&rft.pages=np-np&rft.issn=1049-510X&rft_id=info:doi/&rft_dat=%3Cproquest%3E2586833323%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586833323&rft_id=info:pmid/&rfr_iscdi=true